Breckenridge Launches Milnacipran Generic (ANDA 205071) in the U.S. for Fibromyalgia Treatment
U.S. Generic Launch Announcement
Breckenridge Pharmaceutical, Inc., a U.S.-based pharmaceutical company, has announced the official launch of milnacipran hydrochloride tablets in the U.S. market for the treatment of fibromyalgia. This generic version of the branded drug Savella received generic approval (ANDA 205071) from the FDA approximately 10 years ago, in January 2016. The launch was delayed due to long-term patent litigation and settlement agreements with Forest Laboratories, the original developer of Savella. After a long wait, the product was officially launched in March 2026, marking its full entry into the market.
Indication and Mechanism of Action
Milnacipran hydrochloride is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) that works by blocking the reuptake of serotonin and norepinephrine, neurotransmitters in the brain. Notably, in the U.S., this drug is approved solely for the management of fibromyalgia, and not for depression. It strengthens the pain regulation pathways in the central nervous system, effectively alleviating chronic pain experienced by patients. It is available in various strengths (12.5mg, 25mg, 50mg, 100mg) to support precise dosage adjustments based on the patient's condition.
Competitive Landscape with the Original Product
In the U.S. fibromyalgia treatment market, Savella is one of only three FDA-approved drugs, alongside Lyrica (pregabalin) from Viatris and Cymbalta (duloxetine) from Eli Lilly. This indicates a high barrier to entry in this therapeutic area. The launch of Breckenridge's generic product is expected to position it as a strong competitor to the existing branded product. The availability of a more affordable generic option will likely erode the market share of the original product and provide significant economic relief to chronic pain patients who previously faced high treatment costs.
Growth and Outlook for the Generic Market
The global fibromyalgia treatment market is currently valued at approximately $2.3 billion to $3.6 billion and is steadily growing each year. Breckenridge has proactively established a stable supply chain through a strategic manufacturing partnership with its Indian partner, Centaur Pharmaceuticals. Leveraging this, the company is actively targeting retail and mail-order pharmacy channels to rapidly expand its market presence. Given the chronic nature of the disease and the high rate of long-term prescriptions, this product is expected to become a solid revenue driver for the company in the future.
Breckenridge's launch of milnacipran generic represents a significant regulatory milestone that is poised to reshape the U.S. fibromyalgia treatment market, which is valued at approximately $2.3 billion to $3.6 billion. This launch marks the culmination of a process that began with the FDA's ANDA approval in 2016, but was delayed by patent barriers held by the original Savella. In the short term, increased price competition with existing standard treatments such as pregabalin and duloxetine is expected. In the medium to long term, the company's strategic outsourcing manufacturing agreement with Centaur Pharmaceuticals will enable it to maximize cost competitiveness and secure a stable market share in North America. This is a prime example of a successful strategy involving the timing of generic entry after patent expiration and portfolio diversification through overseas CMO partnerships.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA205071